title: Effect of photodynamic therapy on recurrent pituitary adenomas: clinical phase I/II trial--an early report.
abstract: Pituitary adenomas, although histologically benign, are not always curable by surgery alone, principally because of dural infiltration, as well as their peculiar anatomical location. Radiotherapy has been employed as an adjuvant therapy to address residual disease with favourable results. This approach is, however, not without side effects, and it cannot be repeated. We are therefore investigating the effectiveness of photodynamic therapy (PDT) on recurrent pituitary adenomas in humans. This study details the protocol applied to 12 patients with recurrent pituitary adenomas, which involved systemic administration of photosensitizer (Photofrin) followed, after a period of 24-48 h, by intraoperative illumination of the tumour bed using 630 nm laser light. The primary end points were visual, endocrine and radiological improvement. The incidence of side effects was also monitored. The longest follow-up is 2 years. Most patients suffering from visual acuity or field defects have shown improvement when followed for 12 months or more. Three patients showed complete recovery of their visual fields. All those who presented with functional adenomas have shown reduction in their hormone levels. Tumour volume, relative to the preoperative size, was 122, 87, 66, 60 and 46% at 4 days, and 3, 6, 18 and 24 months, respectively. One patient developed severe skin photosensitization due to early exposure to direct sunlight and three others displayed minor skin reactions. There was no treatment-related mortality or morbidity. One patient (operated transcranially) developed hemiparesis postoperatively, which recovered completely. We think this is unrelated to the treatment. This prospective study demonstrates that PDT may be safely applied to the pituitary fossa by the trans-sphenoidal route and indicates the need for a randomized, controlled trial in order to establish its therapeutic potential.
authors.affiliation: Department of Neurosurgery, General Infirmary at Leeds, UK.
authors.forename: P V
authors.initials: PV
authors.lastname: Marks
authors.forename: P E
authors.initials: PE
authors.lastname: Belchetz
authors.forename: A
authors.initials: A
authors.lastname: Saxena
authors.forename: U
authors.initials: U
authors.lastname: Igbaseimokumo
authors.forename: S
authors.initials: S
authors.lastname: Thomson
authors.forename: M
authors.initials: M
authors.lastname: Nelson
authors.forename: M R
authors.initials: MR
authors.lastname: Stringer
authors.forename: J A
authors.initials: JA
authors.lastname: Holroyd
authors.forename: S B
authors.initials: SB
authors.lastname: Brown
mesh_terms: D000236:Adenoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010778:Photochemotherapy / Q000379:methods*; D010865:Pilot Projects; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery